Both Pfizer-BioNTech and Moderna have submitted requests to the FDA to get their shots authorized for emergency use inyounger children, but it's unclear when they'll becomeavailable. Wednesday, 01 March 2023 01:40 PM EST. Recent exposure to SARS-CoV-2 is not a contraindication or precaution to COVID-19 vaccination. We've also left space for you to tell us anything you want to share about how COVID has affected your life. From April, another bivalent COVID-19 vaccine will be available after the Australian Technical Advisory Group on Immunisation (ATAGI) approved Modernas second Omicron-specific vaccine. The Medical Profession is populated by Psychopaths! For children aged under 12, Pfizers original COVID-19 vaccine is currently the only formulation recommended for use by ATAGI. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose. The bivalent booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. With fall in full swing, experts recommend getting a flu shot and COVID "The vast majority of vaccinated people haven't even gotten a booster. CDC data shows only about 1.5% of eligible Americans have gotten their shot since the rollout. Allergy-related contraindication to a different type of COVID-19 vaccine, Non-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine, Anaphylaxis after non-COVID-19 vaccines or injectable therapies, Vaccine administration errors whether or not associated with an adverse event, Cases of Multisystem Inflammatory Syndrome(MIS) in adults and children, Cases of myocarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine, Cases of pericarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine, Cases of COVID-19 that result in hospitalization or death, Local: Pain at the injection site, sometimes severe, Local: Pain/tenderness at the injection site, Systemic: Fatigue; in the youngest children (ages 623 months), irritability/crying and drowsiness/sleepiness, Local reactions: Pain/tenderness, redness, and swelling at the injection site, Systemic symptoms: Fatigue/malaise, headache, and muscle pain, After reviewing available data on the risks and benefits (see, People, especially males ages 1239 years, should be made aware of the rare risk of myocarditis and pericarditis following receipt of these vaccines and the benefit of COVID-19 vaccination in reducing the risk of severe outcomes from COVID-19, including the possibility of, Counseling should include the need to seek care if. "That, to me, is a victory because as an infectious disease doctor, I'm more concerned that people dont come into the hospital, are not put in the ICU and do not die.". Rare cases of myocarditis and pericarditis have occurred most frequently, although not exclusively, in adolescent and young adult males within the first week after receiving the second dose or a booster dose of an mRNA COVID-19 vaccine. Marketing cookies are used to track visitors across websites. The bivalent mRNA booster dose is administered at least 2 months after completion of the primary series. "All roads lead to an annual COVID booster," Chin-Hong told KQED. 5. Contributing: Karen Weintraub, USA TODAY. The monovalent Novavax booster dose is administered at least 6 months after completion of any primary series and cannot be used in people who previously received any booster dose(s). Local reactions include pain/tenderness, swelling, and erythema at the injection site. Bivalent mRNA vaccines are not authorized at this time for primary series doses with the following exception: children ages 6 months4 years who receive 2 primary series doses of a monovalent Pfizer-BioNTech vaccine should receive a bivalent Pfizer-BioNTech vaccine as their third primary series dose. The BA.5 strainisthe predominant variantcirculating the country, making up more than 85% of new COVID-19 cases in the U.S., according to the CDC. The CDC now recommends that children ages 5 through 11 who have moderately or severely weakened immune systems should get an additional primary shot Currently, only the bivalent Moderna booster dose is authorized for children in this age group who complete a Moderna primary series. For example, people who become moderately or severely immunocompromised after completing a 2-dose mRNA primary series do not need additional primary doses; however, they should follow the schedule for people who are moderately or severely immunocompromised for the booster dose. THE DAY the CDC committee approved mRNA vaccine fir children, a reporter asked, how do you know this vaccine is safe for children. To his credit, his answer was truthful. They are supposed to take the original vaccine or two doses of their original and one dose of the adapted vaccine. Subsequent COVID-19 vaccine dose(s) should be deferred at this time until additional data are available. The Idea of even applying for an Emergency Use COVID Booster for Toddlers is pure Insanity. Studies that compared coadministration of COVID-19 vaccines and seasonal influenza vaccines with separate administration of these vaccines found similar levels of immunogenicity and similar or slightly higher reactogenicity; no specific safety concerns were identified. YL RCyExp-cKd MIS-A, a similar condition in adults, is even rarer and less well characterized. Gavin Newsom. Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and have also been reported during post-authorization use outside the United States. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose. Children ages 611 years: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies. The FDA Authorized a COVID-19 Booster Shot for Immunocompromised People. The objective of this trial is to compare the immunogenicity and the safety of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) to a A COVID booster shot is an additional dose or doses of a vaccine given after the protection provided by the original shot(s) has A mixed primary series composed of any combination of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines is not authorized. Administration of COVID-19 vaccines should not be delayed in patients taking immunosuppressive therapies. %PDF-1.6 % Viral testing to assess for acute SARS-CoV-2 infection or serologic testingto assess for prior infection is not recommendedfor the purpose of vaccine decision-making. "One for the flu shot and the other for the COVID shot.". See also COVID-19 vaccination and myocarditis and pericarditis and Vaccine reactions and adverse events for Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines. Person starts but unable to complete a primary series with the same COVID-19 vaccine due to a contraindication. Under that approach, most people would be advised to get the latest version of the vaccine annually, likely in the fall or winter, similar to the flu vaccine. People ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. This is meant to complete the series for children, Reuters reports. Children age 5 years: A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The updated bivalent booster, which comes as a single dose, protects against both the original virus strain and the omicron variants that have emerged and remain dominant. For the primary series, the first and second doses are separated by 4 weeks and the second and third doses are separated by at least 4 weeks. Experts view clinical recovery, including return to baseline cardiac function, as an important factor when considering COVID-19 vaccination. The authors explain: In this study, we estimated effectiveness starting from day 7 after the third dose, which is similar to the period used to define full vaccination after the second dose. Revaccination with Moderna, Novavax, or Pfizer-BioNTech COVID-19 vaccine (regardless of vaccine administered for initial vaccination) should follow the recommended schedule and cannot exceed the number of primary series and booster doses currently authorized (Table 3). Unless people have a contraindication to vaccination, they should be encouraged to complete the series to optimize protection against COVID-19 even if they experience local or systemic symptoms following the first dose. CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Last week, the companies also filed an application to the FDA for a full approval of their Omicron-adapted COVID vaccine as a primary course and a booster dose for individuals 12 years of age and above. Whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. The primary series doses are separated by 3-8 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Health experts say immunity from the bivalent booster should carry through the holiday season, which will not only protect the person getting vaccinated, but also vulnerable loved ones during family gatherings. See COVID-19 vaccination and myocarditis and pericarditisfor additional information. But this may not be the same for other COVID-19 vaccine boosters. In rare instances, administration of certain combination vaccinesor more than one vaccine at the same clinic visit has been associated with an increased risk of febrile seizures in infants and young children. Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and through passive surveillance during post-authorization use outside the United States. Three doses of Pfizer and BioNTech s vaccine provide a high level of protection against the omicron variant of the virus that causes Covid-19, the companies Where it stands in the U.S.: Available now for many people.The F.D.A. A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used inlimited situationsin people ages 18 years and older who completed any FDA-approved or FDA-authorized monovalent primary series, have not received any previous booster dose(s), and are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. History of myocarditis or pericarditis after a dose of an. People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine, Active treatment for solid tumor and hematologic malignancies, Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia), Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy, Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy), Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome), Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm, Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents), Current or planned immunosuppressive therapies, Optimization of both the patients medical condition and anticipated response to vaccination. People with a history of a non-severe, immediate (onset less than 4 hours) allergic reaction after a dose of, Moderate or severe acute illness, with or without fever. Contraindications and precautions to COVID-19 vaccination, Special situation: People with a known allergy to polysorbate have a contraindication to both Novavax and Janssen COVID-19 vaccines. Antipyretic or analgesic medications can be taken for the treatment of post-vaccination local or systemic symptoms but should not be used prophylactically for prevention of post-vaccination symptoms. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who complete a Pfizer-BioNTech primary series. See FDA EUA fact sheets for a full list of vaccine ingredients. Systemic reactions include fever, fatigue/malaise, headache, chills, myalgia, arthralgia; among younger children, particularly those younger than ages 3 years, systemic reactions also can include irritability/crying, sleepiness, and loss of appetite. Across California, around a quarter of residents have received the bivalent booster and 61% got the initial vaccine. All adults can now get a booster if its been six months or longer since their last COVID-19 booster or confirmed infection, whichever is most recent, Minister Butler said. People with known current SARS-CoV-2 infection should defer any COVID-19 vaccination, including booster vaccination, at least until recovery from the acute illness (if symptoms were present) and criteriato discontinue isolation have been met. Febrile seizures are uncommon after vaccination and were rare in mRNA COVID-19 vaccine clinical trials for infants and young children. Modernas latest bivalent vaccine was granted provisional approval by the Therapeutic Goods Administration (TGA) on 17 February and is expected to be available in Australia from April. For the majority of people who have been infected with COVID already, that experience provides them with a layer of immunity also. White House COVID-19 coordinator Dr. Ashish Jha said everyoneshould get their bivalent booster shot by Oct. 31. The cost-benefit analysis doesnt warrant these frequent shots. COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. Chin-Hong said that hes more concerned about low uptake for the bivalent booster overall, rather than additional doses in people who are up to date with their shots. In the following exceptional situations, a different COVID-19 vaccine may be administered to complete a primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose (no Vaccine Adverse Event Reporting System [VAERS] report is required): The same monovalent vaccine product should be used for all doses in the primary series with the following exception: children ages 6 months4 years who received 2 primary series doses of a monovalent Pfizer-BioNTech vaccine should receive a bivalent Pfizer-BioNTech vaccine as their third primary series dose. Each day, every update from those retro baits made my HEAD EXPLODE. Moderna, Novavax, or Pfizer-BioNTech) may be given orthopoxvirus vaccine (either JYNNEOS or ACAM2000) without a minimum interval between vaccinations. Follow Adrianna Rodriguez on Twitter: @AdriannaUSAT. The bivalent mRNA booster dose is administered at least 2 months after the additional dose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. You will be subject to the destination website's privacy policy when you follow the link. Answer: Clinical trials in people have yet to be completed, but health experts say there are no safety concerns with the bivalent booster. The U.S. health regulator currently authorizes the Omicron-adapted vaccine as the third dose of the countrys three-dose primary course of vaccination for children in this age group. People ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The immune system recognizes those vaccine-created spike proteins as invaders and creates antibodies to block future attacks of the real virus. Some studies in adolescents (ages 1217 years) and adults have shown the small risk of myocarditis and pericarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness might be increased with an interval longer than 4 weeks. Studies show combining AstraZenecas COVID-19 vaccine with a boost from the Pfizer shot (or sometimes Moderna) was more effective than getting another dose of AstraZeneca. A monovalent Pfizer-BioNTech vaccine is used for the first and second primary series doses; a bivalent Pfizer-BioNTech vaccine is used for the third primary series dose. COVID-19 vaccines are not recommended for post-exposure prophylaxis. Currently, children in this age group who receive a mixed 3-dose primary series with any combination of Moderna and Pfizer-BioNTech vaccines cannot receive any booster dose until age 5 years (see Appendix D). What do bivalent vaccines mean for Australias rollout. The risk of recurrence of a dysregulated immune response following reinfection with SARS-CoV-2 or an MIS-like illness following COVID-19 vaccination is unknown. For the primary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at least 4 weeks. March 11, 2022, 11:21 AM PST. For primary series vaccination, three monovalent COVID-19 vaccines (listed in alphabetical order by manufacturer), are recommended: Moderna, Novavax, and Pfizer-BioNTech. Adverse events that occur in a recipient following COVID-19 vaccination should be reported to VAERS. I began that research the first day I heard the word,Covid. Thus, I realized EARLY, nearly EVERYTHING we were hearing from Fauci, Birx, Hahn, Redfield were not JUST lies but DAMNED lies. 2/03/2023 12:03:32 AM, Terms and conditions | Privacy statement | RACGP | recruitGP | AJGP, 2018 The Royal Australian College of General Practitioners (RACGP) ABN 34 000 223 807. Anyone who is currently eligible to receive a first or second booster will now receive the Pfizer Bivalent vaccine. Table 4. Thereporting rates for myocarditis after mRNA COVID-19 primary series vaccination or booster vaccination exceed the background rates in several age groups in males and females with the highest rates observed in males ages 1239 years; see the. Although there's limited data, health experts agree the new boosters are safe and will provide broader protection against omicron variants. The benefit of vaccination outweighs the risks for most people. hbbd```b``o@$"9[h"H"'k@$W$= Based on the overall data to date, the risk for myocarditis and pericarditis after an mRNA COVID-19 booster dose in adolescents and young adults appears generally similar to or lower than the risk after a second mRNA COVID-19 vaccine primary series dose. Our group previously showed that VidPrevtyn Beta, administered as a third vaccine dose, induces higher immune response than the mRNA BNT162b2 vaccine (Comirnaty, BioNTech-Pfizer), against Beta variant but also others variants of concern (VOC) including Omicron BA1 (20) and Omicron BA4/5 (data submitted for publication). You can review and change the way we collect information below. Pfizer/BioNTech applied for emergency use authorization of their Omicron-adapted COVID-19 vaccine in the United States. This includes people with prolonged post-COVID-19 symptoms and applies to primary series and booster doses. Pfizer is close to submitting data to the Food and Drug Administration on a fourth dose of its COVID-19 vaccine, according to CEO Albert Bourla. FDA commissioner Dr. Robert Califf said that ifthe agency waited until studies were completed in another month or two, "the (COVID) wave will have passed us by and the damage will have been done. Print. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. March 1 (Reuters) Pfizer Inc. and its German partner BioNTech SE have applied for emergency use authorization of their Omicron-adapted COVID-19 vaccine in the United States as a booster dose for children aged six months through four years, the companies said on Wednesday. Its given as a full dose - the same as for the first and second doses. Find where to get a COVID bivalent booster near you. Fact is, HOME SCHOOLED students have for YEARS been out performing public school students, IN EVERY SUBJECT on standardized tests. Its been almost six months since the bivalent COVID vaccine booster became available. Cookies are small text files that can be used by websites to make a user's experience more efficient. COVID vaccinations will continue to be free or covered by insurance after the federal COVID emergency order ends on May 11, U.S. health officials have announced. Deciding which booster shot to get can feel a lot like a choose-your-own-adventure book youve got three options, but dont have a clue which one leads to the best outcome. There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children younger than age 6 months. Studies have shown that increased time between infection and vaccination might result in an improved immune response to vaccination. In general, CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination (Table 1) in accordance with the recommended intervals for that age group (3). ", Boosters forkids:Pfizer-BioNTech asks FDA to authorize new omicron-targeting COVID booster for children 5 to 11. Two crossed lines that form an 'X'. The primary series dose and the additional dose are separated by at least 4 weeks. *, Abbreviations: MIS-C = multisystem inflammatory syndrome in children; MIS-A = multisystem inflammatory syndrome in adults. Among adults ages 18 years and older who received the Novavax booster dose, symptoms were more frequently reported after the booster dose than dose 2 of the primary series. Would love your thoughts, please comment. As the country enters flu season,health officials are encouragingAmericans to get their flu shot and COVID-19 booster in the same visit. About COVID-19 Vaccines View the COVID-19 Vaccination Schedule for People who are NOT Moderately or Severely Immunocompromised. In younger children, symptoms of myocarditis might also include non-specific symptoms such as irritability, vomiting, poor feeding, tachypnea, or lethargy. For complicated situations, not addressed by the guidance above, healthcare and public health professionals may consider requesting a consultation from theClinical Immunization Safety Assessment COVIDvaxproject. People who previously received orthopoxvirus vaccination (either JYNNEOS or ACAM2000), particularly adolescent or young adult males, might consider waiting 4 weeks before receiving a COVID-19 vaccine (i.e. By July, Biden tapped by Obama to manage the outbreak, gave orders to STOP COLLECTING DATA on the numbers of infections. The bivalent booster combines the original vaccine and a reformulation targeting a mutated spike protein found on theomicron BA.4 and BA.5 variants, so the immune system can createantibodies that combat both the original coronavirus and the omicron variants. EVA, is a simple callback service to help people book a COVID-19 vaccine. Log in below to join the conversation. We dont know what this does to children, and they really arent dying from COVID-19. Although some reduction in vaccine-induced antibody titerswas observed in people who previously received antibody products, the clinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even considering the possibility of diminished vaccine effectiveness in this situation. Read More. These findings suggest that an increased risk for these conditions might be present after receiving Novavax COVID-19 vaccine. Defer vaccination until the illness has improved. Pfizer/BioNTech applied for emergency use authorization of their Omicron-adapted COVID-19 vaccine in the United States. The Biden administration also urges Americans to take advantage of its vaccine locator website, vaccines.gov. 3. Pfizer and Moderna's bivalent booster both use mRNA technologycombining the original COVID-19 vaccine along with the reformulation targeting theBA.4 and BA.5 versions of the omicron variant. History of anaphylaxis after any vaccine other than COVID-19 vaccine or after any injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., allergy shots]). Meanwhile, when it comes to possible side effects such as myocarditis and pericarditis, the risk following Modernas bivalent BA.4/5 vaccine does not appear to be greater than the risk after a first booster dose of Moderna original vaccine or a booster dose of Pfizer bivalent BA.4/5 vaccine in adolescents and adults aged 12 years and above at this time, according to ATAGI. Stay in touch. A monovalent vaccine is administered for the first and second doses, which are separated by 3 weeks. Use of the monovalent Novavax booster dose in limited situations, Table 2. A Pfizer booster is one full dose of Pfizer vaccine, according to the FDA. Local health departments are encouraging everyone to get the bivalent COVID booster if they have not yet already. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies. People ages 6 months and older are recommended to receive 1 bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized primary series or previously received monovalent booster dose(s)with the following exception: children 6 months4 years who receive a 3-dose Pfizer-BioNTech primary series are not authorized to receive a booster dose at this time regardless of which Pfizer-BioNTech vaccine (i.e., a monovalent or bivalent) was administered for the third primary series dose. What is a COVID-19 vaccine booster? Infrequently, people who have received dermal fillers might experience temporary swelling at or near the site of filler injection (usually face or lips) following a dose of an mRNA COVID-19 vaccine. COVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of a history of symptomatic or asymptomatic SARS-CoV-2 infection. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Vials of the Pfizer-BioNTech COVID-19 Vaccine with a maroon vial cap and maroon label border might state Age 2y to < 5y or Age 6m to <5 yr. Carton labels might state For age 2 years to <5 years or For age 6 months to <5 years. Vials with either printed age range can be used for children ages 6 months4 years. Children ages 611 years: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. Safeway pharmacist Shahrzad Khoobyari (right) administers a Pfizer COVID-19 booster shot into the arm of Chen Knifsend at a San Rafael vaccine clinic on Oct. 1, 2021. Saving Lives, Protecting People, Summary Document for Interim Clinical Considerations, COVID-19 Vaccination Schedule Infographic, COVID-19 Vaccination Schedule Infographic (Immunocompromised), Special Situations for COVID-19 Vaccination of Children and Adolescents: Age Transitions and Interchangeability, FAQs for the Interim Clinical Considerations, general best practice guidelines for immunization (GBPG), U.S. COVID-19 Vaccine Product Information, People who received COVID-19 vaccine outside the United States, People who received COVID-19 vaccine as part of a clinical trial, Interchangeability of COVID-19 vaccine products, Transitioning from a younger to older age group, Considerations for extended intervals for COVID-19 vaccineprimary series doses, COVID-19 vaccination and SARS-CoV-2-infection, COVID-19 vaccination and myocarditis and pericarditis, general best practices for vaccination of people with altered immunocompetence, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host, Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies, People who are moderately or severely immunocompromised, See COVID-19 vaccination and myocarditis and pericarditisfor additional information, Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination, Clinical Immunization Safety Assessment COVIDvax, Considerations for extended intervals for COVID-19 vaccine primary series doses, general best practice guidelines for immunization, symptoms consistent with SARS-CoV-2 infection, reduction in vaccine-induced antibody titers, reduced risk of severe disease including potential recurrence of MIS-C after reinfection, Consultation for decisions about COVID-19 vaccination, testing for current or prior SARS-CoV-2 infection, Clinical Immunization Safety Assessment COVIDvaxproject, Revised SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination, National Center for Immunization and Respiratory Diseases, Use of COVID-19 Vaccines in the U.S.: Appendices, Myocarditis and Pericarditis Considerations, Jurisdictions: Vaccinating Older Adults and People with Disabilities, Vaccination Sites: Vaccinating Older Adults and People with Disabilities, Vaccinating Patients upon Discharge from Hospitals, Emergency Departments & Urgent Care Facilities, Vaccines for Children Program vs. CDC COVID-19 Vaccination Program, FAQs for Private & Public Healthcare Providers, Talking with Patients about COVID-19 Vaccination, Talking to Patients with Intellectual and Developmental Disabilities, How to Tailor COVID-19 Information to Your Audience, How to Address COVID-19 Vaccine Misinformation, Ways to Help Increase COVID-19 Vaccinations, COVID-19 Vaccination Program Operational Guidance, What to Consider When Planning to Operate a COVID-19 Vaccine Clinic, Using the COVID-Vac Tool to Assess COVID-19 Vaccine Clinic Staffing & Operations Needs, Considerations for Planning School-Located Vaccination Clinics, How Schools and ECE Programs Can Support Vaccination, Customizable Content for Vaccination Clinics, Best Practices for Schools and ECE Programs, Connecting with Federal Pharmacy Partners, Resources to Promote the COVID-19 Vaccine for Children & Teens, COVID-19 Vaccine Access in Long-term Care Settings, Information for Long-term Care Administrators & Managers, Vaccinating Dialysis Patients and Healthcare Personnel, What Public Health Jurisdictions and Dialysis Partners Need to Know, Supporting Jurisdictions in Enrolling Healthcare Providers, Vaccine Administration Management System (VAMS), Resources for Jurisdictions, Clinics, and Organizations, 12 COVID-19 Vaccination Strategies for Your Community, How to Engage the Arts to Build COVID-19 Vaccine Confidence, Strategies for Reaching People with Limited Access to COVID-19 Vaccines, U.S. Department of Health & Human Services, History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine, History of a known diagnosed allergy to a component of the COVID-19 vaccine.